Alnylam Pharmaceuticals Inc (ALNY):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Alnylam Pharmaceuticals Inc (ALNY) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7398
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late stage product candidates include Patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis, Inclisiran for hypercholesterolemia, Fitusiran for hemophilia and rare bleeding disorders and Givosiran for acute hepatic porphyrias. It operates subsidiaries in the US, Canada, France, Germany, Italy, Spain, Sweden, the Netherlands, Switzerland and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Alnylam Pharmaceuticals Inc, Medical Equipment, Deal Details 11
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 11
Equity Offering 12
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 19
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 20
Alnylam Pharmaceuticals Inc – Key Competitors 22
Alnylam Pharmaceuticals Inc – Key Employees 23
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 25
Recent Developments 26
Financial Announcements 26
Aug 02, 2018: Alnylam Pharmaceuticals reports second quarter 2018 financial results and highlights recent period activity 26
May 03, 2018: Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity 30
Feb 08, 2018: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity 33
Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 36
May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 38
Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 40
Corporate Communications 43
Oct 10, 2018: Alnylam appoints Dr. Margaret Hamburg to Board of Directors 43
Jun 20, 2018: Alnylam Pharmaceuticals Announces Senior Management Changes 44
May 15, 2018: Alnylam Appoints Colleen Reitan to the Board of Directors 45
Jun 19, 2017: Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term 46
May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 47
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 49
Legal and Regulatory 50
Oct 03, 2018: Kessler Topaz Meltzer & Check: securities fraud class action filed Against Alnylam Pharmaceuticals 50
Apr 20, 2018: Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam 51
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 52
Product News 53
Oct 11, 2018: US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam 53
Jun 12, 2017: Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Alnylam Pharmaceuticals Inc, Medical Equipment, Key Facts, 2017 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Alnylam Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 9
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 11
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 12
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 14
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 16
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 18
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 19
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 20
Alnylam Pharmaceuticals Inc, Key Competitors 22
Alnylam Pharmaceuticals Inc, Key Employees 23
Alnylam Pharmaceuticals Inc, Subsidiaries 24
Alnylam Pharmaceuticals Inc, Joint Venture 25

List of Figures
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Alnylam Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Alnylam Pharmaceuticals Inc (ALNY):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rizal Commercial Banking Corp (RCB):電力:M&Aディール及び事業提携情報
    Summary Rizal Commercial Banking Corp (RCBC) is a commercial and financial banking service provider that offers corporate, commercial, and consumer banking, cash management, treasury, and remittance products and services. The company’s electronic banking services include mobile banking, internet ban …
  • Eguana Technologies Inc. (EGT)-エネルギー分野:企業M&A・提携分析
    Summary Eguana Technologies Inc. (Eguana), formerly Sustainable Energy Technologies Ltd, is a power electronics company. It designs, manufactures and supplies high performance power control solutions for grid interactive energy storage systems. The company’s power control solutions charge and discha …
  • BioGaia AB (BIOG B):企業の財務・戦略的SWOT分析
    BioGaia AB (BIOG B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Fluor Corporation (FLR)-エネルギー分野:企業M&A・提携分析
    Summary Fluor Corporation (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other ser …
  • ADNOC Distribution-石油・ガス分野:企業M&A・提携分析
    Summary ADNOC Distribution, a subsidiary of Abu Dhabi National Oil Company is an integrated energy company. The company carries out the marketing and distribution of petroleum products within the UAE and internationally. The markets and distributes lubes, fuel and gas. The company is also a distribu …
  • Acuity Brands Inc (AYI)-エネルギー分野:企業M&A・提携分析
    Summary Acuity Brands, Inc. (Acuity Brands) provides lighting and building management solutions and services. The company offers lighting solutions including devices such as luminaires, lighting controls, lighting components, power supplies, prismatic skylights, and integrated lighting systems. It a …
  • Enero Group Limited (EGG):企業の財務・戦略的SWOT分析
    Enero Group Limited (EGG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Jardine Cycle & Carriage Limited:企業の戦略・SWOT・財務情報
    Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • BGR Energy Systems Ltd:企業の戦略・SWOT・財務情報
    BGR Energy Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary BGR Energy Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Congenica Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Congenica Ltd (Congenica) is a biotechnology company that offers research and experimental development on biotechnology. The company’s technology SAPIENTIA, is used to personalize patient care through accurate diagnoses, support clinical trials, and drug development. It offers services such …
  • BioLineRx Ltd (BLRX)-医療機器分野:企業M&A・提携分析
    Summary BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company’s product pipeline includes BL-8040, a short peptide for multiple cancer and hematological indicat …
  • SNCF Mobilites Group:企業の戦略・SWOT・財務情報
    SNCF Mobilites Group - Strategy, SWOT and Corporate Finance Report Summary SNCF Mobilites Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mangalore Refinery and Petrochemicals Ltd (MRPL):企業の財務・戦略的SWOT分析
    Mangalore Refinery and Petrochemicals Ltd (MRPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • New Standard Energy Ltd (NSE):企業の財務・戦略的SWOT分析
    Summary New Standard Energy Ltd (NSE), formerly Hawk Resources Ltd, is an oil and gas exploration and production company. The company carries out acquisition, exploration, and develops oil and gas; and hydrocarbon properties. It holds interest in production and development project in the Eagle Ford …
  • Maruho Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Maruho Co Ltd (Maruho) carries out the research, development, production, and distribution of dermatological products. It product portfolio includes a wide range of prescription drugs, medical devices and other skincare products. The company also offers products for infectious disease, ear n …
  • Rapid Pathogen Screening Inc:医療機器:M&Aディール及び事業提携情報
    Summary Rapid Pathogen Screening Inc (RPS) is a biotechnology company that designs, develops, manufactures and markets point-of-care diagnostic tests. The company uses its patented direct sampling micro-filtration and direct multi-planar chromafiltography (DMC) technology to develop various tests. I …
  • Intracom Holdings SA (INTRK):企業の財務・戦略的SWOT分析
    Intracom Holdings SA (INTRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Pharma Two B Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharma Two B Ltd (Pharma Two) is a drug development company that develops and manufactures drugs for the treatment of Parkinson's disease and cancer. The company provides combination products in preclinical state and generic products including P2B 005, P2B 006, P2B 007, P2B 008 and P2B 009, …
  • Harley-Davidson, Inc.:企業の戦略・SWOT・財務情報
    Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report Summary Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Rich Pharmaceuticals Inc (RCHA):製薬・医療:M&Aディール及び事業提携情報
    Summary Rich Pharmaceuticals Inc (Rich Pharmaceuticals) is a biopharmaceutical company that offers discovery and development of therapies for the treatment of acute myelogenous leukemia (AML) in refractory patients. The company’s pipeline portfolio offers a lead drug candidate for the treatment of a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆